AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23491407
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (n = 6)
Trial: 20153492
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (0.05 μg/[kg min])
Trial: 19187819
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral treatment (GCBT)
Trial: 15251401
Drug: Oral chloramphenicol
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chloramphenicol (500 mg every six hours for five days)
Trial: 7660719
Drug: Pill-combined and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill-combined and GnRH
Trial: 28556962
Drug: 12-h IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-h IV retosiban followed by a single dose of oral placebo (R-P)
Trial: 28556962
Drug: 12-h IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-h IV placebo followed by single-dose oral retosiban (P-R)
Trial: 25074756
Drug: Topical brimonidine
RxNorm normalized name: brimonidine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical brimonidine tartrate (BT) 0.5% gel, applied once daily for 4 weeks
Trial: 25074756
Drug: Vehicle gel,
RxNorm normalized name: vehicle gel, anacaulase-bcdb TOPICAL GEL (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel, applied once daily for 4 weeks
Trial: 17919545
Drug: Garenoxacin 400
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Garenoxacin 400 mg QD for 5 days
Trial: 17919545
Drug: Garenoxacin 400
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Garenoxacin 400 mg QD for 10 days
Trial: 17919545
Drug: Garenoxacin 400
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Garenoxacin 400 mg QD for 5 or 10 days
Trial: 15688694
Drug: Kangfu Xiaozheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangfu Xiaozheng Tablet
Trial: 15688694
Drug: Guizhi Fuling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guizhi Fuling Pill
Trial: 11160062
Drug: Ketoprofen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (300 mg)
Trial: 2643965
Drug: Analgesics and
RxNorm normalized name: Analgesics and anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics and a standard circumferential rib belt (Zimmer Universal Rib Belt)
Trial: 2643965
Drug: Oral analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesics alone
Trial: 29753538
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OAC) indication
Trial: 23089925
Drug: Statins treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins treatment for 2 weeks
Trial: 20166405
Drug: Combination (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (one session plus HB)
Trial: 16047223
Drug: Levamisole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 2.5 mg/kg on alternate days
Trial: 16047223
Drug: I.V. cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. cyclophosphamide 500 mg/m2/month for six months
Trial: 10820175
Drug: 15 mg/d
RxNorm normalized name: Valtoco, 15 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/d folic acid
Trial: 10820175
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d folic acid
Trial: 10820175
Drug: 60 mg/d
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/d folic acid
Trial: 10820175
Drug: 60 mg/d
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/d folic acid in MTHFR 677TT genotype patients
Trial: 10820175
Drug: 30 or
RxNorm normalized name: Oseni 25/30 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 or 60 mg/d folic acid
Trial: 1514338
Drug: Intermittent wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent wound infiltration with bupivacaine and continuous coeliac plexus blockade (total 862.5 mg over 12 h)
Trial: 6341873
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral taurine administration
Trial: 29943100
Drug: Sub-tenon steroid
RxNorm normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-tenon steroid injection (Triamcinolone acetonide) plus anti-VEGF injection
Trial: 29943100
Drug: Anti-VEGF injection
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF injection only
Trial: 27112245
Drug: Simethicone addition
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone addition group (400 mg)
Trial: 27112245
Drug: Water addition
RxNorm normalized name: WATER 99 mL in 100 mL OPHTHALMIC LIQUID [Water Additive]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water addition group (1 L)
Trial: 11980869
Drug: Granulocyte colony
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Granulocyte colony stimulating factor (G-CSF, 300 microg)
Trial: 6982270
Drug: Cold cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold cardioplegia with topical deep hypothermia using Bretschneider solution
Trial: 31192515
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) injection into the right masseter muscle
Trial: 31192515
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (IS) injection into the right masseter muscle
Trial: 26950019
Drug: Carbamazepine, Lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine, Lithium Carbonate, or Valproic Acid (monotherapy)
Trial: 25426786
Drug: Topical +
RxNorm normalized name: Topicale
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical + intrasulcular hyaluronan gel
Trial: 25426786
Drug: Topical hyaluronan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hyaluronan gel
Trial: 25426786
Drug: Scaling +
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling + topical hyaluronan gel
Trial: 18386255
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Pycnogenol daily (oral capsules)
Trial: 15218810
Drug: Intramuscular interferon-beta
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon-beta Ia
Trial: 9424007
Drug: Nicotinamide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (80 mg/kg/day)
Trial: 8479489
Drug: Atovaquone (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone (750 mg, orally, three times daily for 21 days)
Trial: 8479489
Drug: Trimethoprim (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (320 mg) plus sulfamethoxazole (1600 mg, orally, three times daily for 21 days)
Trial: 15800019
Drug: Half-dose reteplase
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose reteplase plus abciximab
Trial: 15800019
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (standard-dose reteplase and half-dose reteplase plus abciximab)
Trial: 2679829
Drug: Ossein-hydroxyapatite compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ossein-hydroxyapatite compound (OHC) treatment providing 1.6 g calcium, 0.74 g phosphorus, and 1.94 g noncollagen peptides per day
Trial: 2679829
Drug: Ossein-hydroxyapatite compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ossein-hydroxyapatite compound (OHC) treatment
Trial: 4157353
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin (single injection)
Trial: 23580109
Drug: Pirfenidone single
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone single doses (200, 400, and 600 mg)
Trial: 23580109
Drug: Pirfenidone multiple
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone multiple doses (400 mg, 3 times daily)
Trial: 23580109
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of pirfenidone
Trial: 23580109
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of unchanged pirfenidone
Trial: 19762765
Drug: IVRA lidocaine
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVRA lidocaine and paracetamol (300 mg) admixture plus IV saline (Group 2)
Trial: 19762765
Drug: IVRA lidocaine
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVRA lidocaine plus IV paracetamol (300 mg) (Group 3)
Trial: 14665887
Drug: 1 mmol/l
RxNorm normalized name: cardiopleg/organ preserv no.1 9 mmol-198 mmol-2 mmol-1 mmol/L PERFUSION BOTTLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mmol/l CAP diluted in glucidic solvent
Trial: 14665887
Drug: 100 nMol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 nMol/l RTX diluted in 10% ethanol
Trial: 11197264
Drug: Mesalamine therapy
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine therapy (4 g daily for 18 months)
Trial: 11197264
Drug: Mesalamine therapy
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine therapy (in subgroup with isolated small bowel Crohn's disease)
Trial: 9250794
Drug: Somatostatin receptor
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin receptor scintigraphy (110 or 220 MBq of 111In‐pentetreotide)
Trial: 9425399
Drug: Somatostatin receptor
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin receptor scintigraphy
Trial: 28527646
Drug: Tight glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glucose control (4-6 mmol/l, IV insulin, n = 9)
Trial: 28527646
Drug: Standard glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glucose control (6-10 mmol/l, SC insulin, n = 9)
Trial: 26179771
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg teriparatide (PTH 1-34 (Forteo)) for 4 weeks
Trial: 19140845
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 or 3 times per week administration of epoetin-beta)
Trial: 8878339
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment administered when well
Trial: 8878339
Drug: No bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bright light treatment until first symptoms of depression
Trial: 1300312
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg, two tablets a day for 90 days)
Trial: 31722024
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone hydrochloride 800 μg per 1 mL
Trial: 31722024
Drug: Intramuscular naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular naloxone hydrochloride 800 μg per 1 mL
Trial: 19461552
Drug: TENS (45-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS (45-min treatment, sensory, biphasic square wave stimulation, 150-mus phase duration, 150 pps)
Trial: 19461552
Drug: Focal knee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal knee joint cooling (20-min treatment with two 1.5-L ice bags)
Trial: 17717439
Drug: Standard burn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard burn care plus oxandrolone (0.1 mg/kg body weight q.12 hours p.o, n = 45)
Trial: 742355
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with Melfalan (Group A)
Trial: 742355
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with adriamycin and Melfalan (Group B)
Trial: 742355
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with Melfalan (Group A) among premenopausal patients
Trial: 742355
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with adriamycin and Melfalan (Group B) among premenopausal patients
Trial: 742355
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with Melfalan (Group A) among postmenopausal patients
Trial: 742355
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with adriamycin and Melfalan (Group B) among postmenopausal patients
Trial: 6981171
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 320 mg of TMP and 1,600 mg of SMZ daily for 14 days
Trial: 6981171
Drug: Chloramphenicol 2
RxNorm normalized name: chloramphenicol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol 2 g daily for 14 days
Trial: 20400416
Drug: Topical alkane
RxNorm normalized name: C12-19 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical alkane vapocoolant spray
Trial: 17592908
Drug: Psychoeducational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational group therapy
Trial: 15273528
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg b.i.d. (n = 198)
Trial: 15273528
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg b.i.d. (n = 198)
Trial: 9342601
Drug: Lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1 mg bid)
Trial: 8518523
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (6 mg/kg/day)
Trial: 8518523
Drug: Cyclophosphamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (2.5 mg/kg/day)
Trial: 8518523
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (children in complete remission and off therapy)
Trial: 17943573
Drug: Intranasal ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal ciclesonide 200 microg once daily
Trial: 17943573
Drug: HFA‐BDP 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA‐BDP 320 microg twice daily during run-in period
Trial: 17943573
Drug: Dexamethasone 2
RxNorm normalized name: dexamethasone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 2 mg on last treatment day
Trial: 11599064
Drug: Injection rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection rate of 0.5 mL/second
Trial: 11599064
Drug: Injection rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection rate of 1.5 mL/second
Trial: 11599064
Drug: Higher injection
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher injection rates (0.5, 1.5, and 3.0 mL/second) in volunteers
Trial: 9725493
Drug: Milnacipran (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (50 mg oral and intravenous doses)
Trial: 7528939
Drug: Nasal decongestant
RxNorm normalized name: Nasal Decongestant
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal decongestant and position
Trial: 7528939
Drug: Nasal decongestant
RxNorm normalized name: Nasal Decongestant
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal decongestant alone
Trial: 7528939
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nasal decongestant and position
Trial: 3169044
Drug: Treatment (quinidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (quinidine, disopyramide or mexiletine)
Trial: 23512974
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (reduction of daily caloric intake by 400 kcal for 6 months)
Trial: 19553555
Drug: N. lactamica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. lactamica OMV vaccine
Trial: 9797642
Drug: Sucrose polyester
RxNorm normalized name: polyester-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose polyester (SPE) 20-40 g daily (mean 26.8 g)
Trial: 2545640
Drug: Dietary fibre
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fibre supplement of 7 g/day for 11 weeks (part I)
Trial: 2545640
Drug: Dietary fibre
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fibre supplement of 6 g/day for 16 weeks (part II)
Trial: 2545640
Drug: Dietary fibre
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fibre supplement of 6 g/day and an ad libitum diet for the rest of the period (part III)
Trial: 1102879
Drug: Sustained-release 40
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release 40 mg dicyclomine hydrochloride tablets (Merbentyl Dospan)
Trial: 1102879
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg plain dicyclomine hydrochloride tablets (Merbentyl)
Trial: 31775518
Drug: N‐acetylcysteine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐acetylcysteine with a combination of nutraceuticals
Trial: 17106751
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of ifosfamide 3 g/m2/day for 3 days (9 g/m2/cycle)
Trial: 17106751
Drug: Short (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short (3 h) infusion of ifosfamide 3 g/m2/day for 3 days (9 g/m2/cycle)
Trial: 17106751
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of ifosfamide
Trial: 17106751
Drug: Short (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short (3 h) infusion of ifosfamide
Trial: 14713402
Drug: Intermittent human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent human parathyroid hormone (PTH) - teriparatide (recombinant human PTH 1‐34), self-administered daily injections.
Trial: 11488370
Drug: Long-term antidepressant
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antidepressant treatment
Trial: 11488370
Drug: Mood-stabilizing agents
RxNorm normalized name: CAPILLARY STABILIZING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood-stabilizing agents alone
Trial: 11488370
Drug: Mood-stabilizing agents
RxNorm normalized name: CAPILLARY STABILIZING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood-stabilizing agents combined with antidepressants
Trial: 10511413
Drug: Azithromycin (8.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (8.0 g total dose over 1 month)
Trial: 2068440
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (5 mg/kg/d)
Trial: 2068440
Drug: Azathioprine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2 mg/kg/d)
Trial: 29628196
Drug: Standardized knee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized knee injection cocktail and oral acetaminophen (standard group)
Trial: 29628196
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine periarticular injection and oral acetaminophen (LB group)
Trial: 29628196
Drug: Standardized knee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized knee injection cocktail and intravenous (IV) acetaminophen (IVA group)
Trial: 28273870
Drug: Fiber cookie
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber cookie (24 g fiber from distarch phosphate)
Trial: 28273870
Drug: Control cookie
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cookie (0.5 g fiber)